Preclinical Studies Demonstrate Galimedix Therapeutics’ Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models

KENSINGTON, Md. and SHORASHIM, Israel, May 08, 2019 (GLOBE NEWSWIRE) — Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today presented data demonstrating its novel, first–in–class, investigational compound GAL–101 provides neuroprotection from misfolded amyloid beta molecules aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues. Further, investigators discovered that peak levels from a single delivery of the compound may provide sustained detoxification. The poster was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Vancouver, British Columbia, Canada from April 28 to May 2, 2019.

"The unique mechanism of action of GAL–101 has been shown to reduce the levels of amyloid beta present in the retina, thereby both preventing neurodegeneration and increasing the chances of preventing vision loss. However, this poster further demonstrates that a single peak administration of the compound by eye drops may also provide a sustained detoxifying effect in dry AMD and glaucoma patients," commented Dr. Hermann Russ, lead author of the paper and Chief Scientific Officer of Galimedix. "These preclinical data, combined with a positive result in the Phase 1 study have made it possible for us to move rapidly toward a Phase 2 program for which we will provide updates when available."

In the poster, investigators reported that eye drops of GAL–101 in repeated monkey models resulted in concentrations in the retina rapidly reaching levels far in excess of the threshold for initiating the peak–related pharmacological effect, and remained in those levels for at least four hours. Furthermore, in age–related macular degeneration (AMD) mouse models with substantial amyloid beta deposits in the retina accumulated during many months, GAL–101 eye drops when given for 1–3 months resulted in substantially less amyloid beta deposits, and simultaneously reduced the levels of C–complement response, which is considered a central factor leading to the progression of dry AMD.

About GAL–101
GAL–101 is a proprietary compound designed to prevent the formation of all forms of toxic amyloid beta oligomers, by binding with high affinity to the misfolded amyloid beta monomers before they can form toxic soluble oligomers. These then rapidly conglomerate into amorphous, non–beta–sheet formations, which we call "clusters," which are innocuous. Interestingly, once GAL–101 concentration reaches effective levels it "triggers" formation of the "clusters", which then have shown the capacity to collect additional misfolded amyloid beta monomers even in the absence of additional GAL–101 molecules, through a self–propagation mechanism. This novel "trigger effect," protected by Galimedix' patent portfolio, results in a sustained effect lasting far longer than the time a single administration of the drug remains at therapeutic levels in the retina, potentially allowing for a convenient interval application regimen for patients. Thus, GAL–101 drops may potentially provide sustained prevention of formation of toxic amyloid beta oligomers in the retina, leading to a reduction of complement response and their consequent damage. Thus GAL–101 could contribute to slowing or stopping progression, and possible restoration of neural function depressed by the chronic toxic attack.

About Galimedix
Based in the United States and Israel, Galimedix is a Phase 2 ready ophthalmic pharmaceutical company with a world class drug development team advancing a novel, patented small molecule drug with a novel MOA addressing glaucoma and dry AMD utilizing an eye drops delivery platform, which may offer significant safety and compliance advantages over commonly used direct ocular injections. Eye drops are used to deliver steroids and other small molecules, like GAL–101, to the retina, and studies with Galimedix's eye drops in monkeys have demonstrated therapeutic levels quickly reaching the retina of the closest model to humans. Compelling efficacy data from GAL–101 eye drops in relevant animal models have demonstrated more than 90 percent neuroprotection, and the compound is supported by several leading experts in glaucoma and in dry AMD who also support the design of the company's proposed Phase 2 studies.

Galimedix has exclusive worldwide license from Tel Aviv University, following return of license by a German pharma (Merz) due to management change and strategic pivot away from neuroscience. The license also includes a next generation, potentially superior molecule intended for oral delivery, with potential to treat retinal and other CNS diseases.

Contact:
Jules Abraham
Core IR
julesa@coreir.com
917–885–7378

Comments are closed

RSS Daily Times Nigeria

  • Daily Times Newspaper, Monday, June 24, 2019
    The post Daily Times Newspaper, Monday, June 24, 2019 appeared first on Daily Times Nigeria. Nigeria News from Nigeria Newspapers
  • Nigeria’s current challenges, signs of greatness, says Osinbajo
    …Urges Nigerians to keep praying for the nation Mathew Dadiya with agency report The Vice President, Professor Yemi Osinbajo (SAN), has said the current challenges facing Nigeria were signs that the country was bound for greatness. Osinbajo made the statement on Sunday while addressing the congregation during service at a branch of the Redeemed Christian […]
  • Commercial banks deposit with CBN hits N1.1trn in 11 days
    …Reduce borrowing to N479bn Motolani Oseni Deposit Money Banks (DMBs) operating in the country have increased their deposits with the Central Bank of Nigeria (CBN) to a whopping N1.14 trillion in just 11 business days, The Daily Times checks revealed. Latest financial data of the CBN, however, showed that a total sum of N479 billion […]
  • SERAP sues CCB, wants asset declaration of public officials made public
    The Socio-Economic Rights and Accountability Project (SERAP) has filed a lawsuit in the Federal High Court, Lagos, against the Code of Conduct Bureau (CCB) over the CCB’s claim that it could not disclose details of asset declarations submitted to it by successive presidents and state governors since 1999 because doing so “would offend the right […]

Weather for Abuja

The location could not be found.

RSS Vanguard News

  • 3 die as Akwa Ibom communities clash over woman’s extra-marital affair
    Uyo—NO fewer than three persons have been reportedly killed following a clash that erupted between Ikot Osute and Ikot Ukpong villages in Oruk Anam Local Government Area of Akwa Ibom State, yesterday. Continue reading 3 die as Akwa Ibom communities clash over woman’s extra-marital affair at Vanguard News.
  • 5 reasons Nigeria will remain poverty capital until 2023
    POSSIBLY, several of the card carrying members of the All Progressives Congress, APC, present clapped lustily when the President made that statement. That is to be expected. Loyal politicians at campaign rallies are not expected to think critically about what their leaders say. Their role is to applaud anything pronounced. Other observers still in possession […]
  • The plight of state pensioners
    It is worrisome that after many years, the National Pension Commission, PENCOM, is reporting that only 15 states have made progress in the implementation of the scheme, while only eight out of the remaining 21 states have sent bills for its enactment. Continue reading The plight of state pensioners at Vanguard News.

© 2019 Nigeria Newsline. All Rights Reserved. Log in -